Organon Signs an Exclusive, Worldwide Licence Agreement on Advanced Antithrombotic Compounds With Endotis Pharma

Oss, The Netherlands (ots/PRNewswire) - Organon, the human
healthcare business unit of Akzo Nobel, today announced that it has
signed an exclusive, worldwide license agreement with Endotis Pharma
concerning the development and commercialization of several
antithrombotic compounds. Endotis is a specialty pharma company
dedicated to the discovery and development of small-glyco drugs for
applications in thrombosis and oncology.

Under the terms of the agreement, Endotis has acquired exclusive
rights to develop and commercialize Org 42675, Org 217609 (a
neutralizable follow-up of Org 42675) and Org 224283, three
antithrombotic compounds with an innovative dual mechanism of action.
Financial details are not disclosed.

Org 42675 and Org 217609 display a new and original dual mechanism
of action, combining blood coagulation factor Xa inhibition and
thrombin inhibition. Org 42675 has successfully completed two phase I
clinical trials. Org 224283 also displays an innovative dual
mechanism of action, combining factor Xa inhibition and an
antiplatelet effect, both effects being neutralizable by a specific
antidote. Org 224283 is at a preclinical-stage of development.

Charles Woler, Chairman and CEO of Endotis Pharma, declared: "We
are delighted to sign this licensing agreement, as these compounds
will strongly reinforce our position in thrombosis. Due to their
oligosaccharide structure, they perfectly fit with our focus on
small-glyco drugs. We are proud that Organon has faith in Endotis to
develop these very promising compounds."

David Nicholson, executive vice president Research and Development
of Organon added: "We are excited to bring this opportunity to
Endotis. Organon will continue to be involved bringing in our
expertise in manufacturing and development. This deal maximizes the
chances of bringing these innovative compounds to patients in need of
anti-thrombotic care."

About Organon

Organon creates, manufactures and markets innovative prescription
medicines that improve the health and quality of human life. Through
a combination of innovation and business partnerships, Organon seeks
to leverage its position as a leading biopharmaceutical company in
each of its core therapeutic fields: fertility, gynecology and
selected areas of anesthesia. It has extensive expertise in
neuroscience and a rich and focused R&D program. Research areas also
include immunology and specific areas of oncology. Organon products
are distributed in over 100 countries worldwide, of which more than
50 have an Organon subsidiary. Organon is the human healthcare
business unit of Akzo Nobel.

About Endotis Pharma

Founded in 2003, Endotis Pharma is a specialty pharma company
dedicated to the discovery and development of small-glyco drugs
(SGDs) for applications in thrombosis and oncology. Endotis Pharma
has built a well-balanced portfolio of pre-clinical and clinical
stage compounds, either in-licensed (from Organon: EP42675, an
anticoagulant that has completed two phase I, EP217609, the
neutralizable form of EP4675 and EP224283, an antithrombotic which is
in preclinicals) or generated by the company's own drug discovery
platform (EP37 program, focused on the oral prevention and treatment
of thrombosis, and EP8000 program in oncology). The SGDs developed by
Endotis are based on fully synthetic oligosaccharides mimicking
glycosaminoglycans, which is the core field of expertise of Endotis'
scientists. Proof of concept has already been established with
synthetic oligosaccharides in cardiovascular/thrombosis, with
oncology being the next promising therapeutic area. Endotis currently
has 28 employees (including 14 PhDs/MDs) based in Paris and Lille
(France). Sofinnova Partners is a lead investor in Endotis Pharma.

Disclaimer: the development of new drug technologies is difficult,
erratic and unpredictable. Endotis Pharma's forecasts and future
economic performance depend on research that has yet to be performed
and on a number of other factors. The company's future economic
performance may differ significantly from that currently forecast.

Safe Harbor Statement Organon(1)

This press release may contain statements which address such key
issues as Akzo Nobel's growth strategy, future financial results,
market positions, product development, pharmaceutical products in the
pipeline, and product approvals. Such statements should be carefully
considered, and it should be understood that many factors could cause
forecasted and actual results to differ from these statements. These
factors include, but are not limited to, price fluctuations, currency
fluctuations, progress of drug development, clinical testing and
regulatory approval, developments in raw material and personnel
costs, pensions, physical and environmental risks, legal issues, and
legislative, fiscal, and other regulatory measures. Stated
competitive positions are based on management estimates supported by
information provided by specialized external agencies. For a more
comprehensive discussion of the risk factors affecting our business
please see our Annual Report on Form 20-F filed with the United
States Securities and Exchange Commission, a copy of which can be
found on the company's corporate website http://www.akzonobel.com.
The 2006 Annual Report on Form 20-F will be available in the second
quarter of 2007.

(1) Pursuant to the U.S. Private Securities Litigation Reform Act
1995.

For more information:
Organon
Monique Mols, director media relations
NV Organon, Oss, the Netherlands
Tel: +31-412-665440
Email: monique.mols@organon.com
Endotis Pharma:
Press: Alize RP
Caroline Carmagnol
+33(0)6-64-18-99-5
caroline@alizerp.com
Investors: Endotis Pharma
Charles Woler, Chairman and CEO
charleswoler@endotis.com
Stéphane Degove , Finance Director
stephanedegove@endotis.com
+33(0)-1-48-46-84-87

Rückfragehinweis:
For more information: Organon, Monique Mols, director media
relations, NV Organon, Oss, The Netherlands, Tel: +31-412-665440,
Email: monique.mols@organon.com; Endotis Pharma: Press: Alize RP,
Caroline Carmagnol, +33(0)6-64-18-99-5, caroline@alizerp.com;
Investors: Endotis Pharma, Charles Woler, Chairman and CEO,
charleswoler@endotis.com, Stéphane Degove, Finance Director,
stephanedegove@endotis.com, +33(0)-1-48-46-84-87

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | PRN

print